舒必利对难治性抑郁症的增效作用

Reinforcing curative effect for refractory depression with sulpiride

目的:探讨文拉法辛缓释胶囊联合小剂量舒必利治疗难治性抑郁症的疗效及安全性。方法:73例难治性抑郁症患者随机分为合用组38例,单用组35例,总疗效8周。于治疗前和治疗2、4、6、8周分别用汉密尔顿抑郁量表(HAMD-17)及治疗中出现的症状量表(TESS)评定疗效及不良反应。结果:两组评分较治疗前均显著下降(P<0.01),但合用组显效率显著较好(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。结论:文拉法辛缓释胶囊联合小剂量舒必利治疗难治性抑郁症疗效明显优于单用文拉法辛缓释胶囊,安全性较好。

Objective： To study curative effect and safety of venlafaxine extended release capsule combined with a low dose of sulpiride for refractory depression. Methods：73 patients with refractory depression were randomly divided into the combined group （n =38 ） and the venlafaxine group（n =35 ） ,treated for 8 weeks. The curative effect and side effect were assessed with Hamilton Depression Rating Scale （ HAMD-17 ） and Treatment Emergent Symptom Scale （ TESS ） re- spectively before treatment and at the end of 2w,4w,6w and 8w. Results：After the treatment, the scores of HAMD-17 sig- nificantly decreased in the 2 groups （P 〈 0.01 ）, but the curative effect in the combined group was significantly better than the venlafaxine group（P 〈 0.05 ） . There was no significant difference in side effect in the 2 groups（ P 〉 0.05 ）. Conclusion：The curative effect of venlafaxine extended release capsule combined with a low dose of sulpiride was signifi- cantly superior to venlafaxine only for refractory depression and the combination was very safe.